Skeletal muscle mitochondrial function and whole-body metabolic energetics in the +/G610C mouse model of osteogenesis imperfecta.


Journal

Molecular genetics and metabolism
ISSN: 1096-7206
Titre abrégé: Mol Genet Metab
Pays: United States
ID NLM: 9805456

Informations de publication

Date de publication:
08 2022
Historique:
received: 19 08 2021
revised: 08 06 2022
accepted: 09 06 2022
pubmed: 22 6 2022
medline: 5 8 2022
entrez: 21 6 2022
Statut: ppublish

Résumé

Osteogenesis imperfecta (OI) is rare heritable connective tissue disorder that most often arises from mutations in the type I collagen genes, COL1A1 and COL1A2, displaying a range of symptoms including skeletal fragility, short stature, blue-gray sclera, and muscle weakness. Recent investigations into the intrinsic muscle weakness have demonstrated reduced contractile generating force in some murine models consistent with patient population studies, as well as alterations in whole body bioenergetics. Muscle weakness is found in approximately 80% of patients and has been equivocal in OI mouse models. Understanding the mechanism responsible for OI muscle weakness is crucial in building our knowledge of muscle bone cross-talk via mechanotransduction and biochemical signaling, and for potential novel therapeutic approaches. In this study we evaluated skeletal muscle mitochondrial function and whole-body bioenergetics in the heterozygous +/G610C (Amish) mouse modeling mild/moderate human type I/VI OI and minimal skeletal muscle weakness. Our analyses revealed several changes in the +/G610C mouse relative to their wildtype littermates including reduced state 3 mitochondrial respiration, increased mitochondrial citrate synthase activity, increased Parkin and p62 protein content, and an increased respiratory quotient. These changes may represent the ability of the +/G610C mouse to compensate for mitochondrial and metabolic changes that may arise due to type I collagen mutations and may also account for the lack of muscle weakness observed in the +/G610C model relative to the more severe OI models.

Identifiants

pubmed: 35725939
pii: S1096-7192(22)00340-7
doi: 10.1016/j.ymgme.2022.06.004
pii:
doi:

Substances chimiques

Collagen Type I 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

315-323

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States
Organisme : NIAMS NIH HHS
ID : R21 AR077813
Pays : United States
Organisme : NIGMS NIH HHS
ID : R25 GM064120
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM135744
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Victoria L Gremminger (VL)

Department of Biochemistry, University of Missouri, Columbia, MO 65211, United States of America.

Catherine L Omosule (CL)

Department of Biochemistry, University of Missouri, Columbia, MO 65211, United States of America.

Tara K Crawford (TK)

Department of Biochemistry, University of Missouri, Columbia, MO 65211, United States of America.

Rory Cunningham (R)

Departments of Nutrition and Exercise Physiology and Medicine-GI, University of Missouri, Research Service-Harry S Truman Memorial VA Hospital, Columbia, MO 65201, United States of America.

R Scott Rector (RS)

Departments of Nutrition and Exercise Physiology and Medicine-GI, University of Missouri, Research Service-Harry S Truman Memorial VA Hospital, Columbia, MO 65201, United States of America.

Charlotte L Phillips (CL)

Department of Biochemistry, University of Missouri, Columbia, MO 65211, United States of America; Department of Child Health, University of Missouri, Columbia, MO 65212, United States of America. Electronic address: phillipscl@missouri.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH